ArticleProstaglandins, leukotrienes, and essential fatty acids
Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study.
Article in Prostaglandins, leukotrienes, and essential fatty acids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- The Role of Docosahexaenoic Acid (DHA) on Cognitive Functions in Psychiatric Disorders.Nutrients · 2019Pooled it
- Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases.Prostaglandins, leukotrienes, and essential fatty acids · 2018Review
- Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations.Translational psychiatry · 2016Article
- Components of a Mediterranean diet and their impact on cognitive functions in aging.Frontiers in aging neuroscience · 2015Review
- Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.CNS drugs · 2014Review
- Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects.Archives of medical science : AMS · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
introductionPatients with schizophrenia have significant cognitive deficits, generally resistant to conventional treatment. This preliminary study examined the effects of ethyl-eicosapentanoate (EPA) on an executive function in early course patients. PATIENTS AND
methodsPatients with schizophrenia were given, after an informed consent, 2 g of an EPA daily for 24 weeks, in an open-label study. The Wisconsin Card Sort Test (WCST) was administered at baseline, weeks 4, 12 and 24.
resultsThe 27 patients, with a mean duration of illness of 4.2 years, were all receiving atypical antipsychotics; treatment remained unchanged for the study. Perseverative errors - the key measure derived from WCST - were significantly reduced from the baseline mean of 28.2 to 18.4 errors at week 24. Positive symptoms also improved significantly. There were no correlations between EPA levels and any clinical or other neuropsychological measures.
conclusionThese findings suggest that an EPA has procognitive effects for patients with schizophrenia, but controlled trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.